Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 10.3389/fphar.2018.01128 Pharmacology Correction Corrigendum: Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR Huang Jun-ming † Ren Ran-yue † Bao Yuan Guo Jia-chao Xiang Wei Jing Xing-zhi Shi Jia Zhang Guo-xiang Li Long Tian Yong Kang Hao * Guo Feng-jin * Department of Orthopedics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Edited and reviewed by: Wolff Mayer Kirsch, Loma Linda University Medical Center (LLUMC), United States

 *Correspondence: Hao Kang kanghao100@vip.sina.com Feng-jin Guo fguo@tjh.tjmu.edu.cn

This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

†These authors have contributed equally to this work

 09 10 2018 2018 9 1128 07 09 2018 14 09 2018 Copyright © 2018 Huang, Ren, Bao, Guo, Xiang, Jing, Shi, Zhang, Li, Tian, Kang and Guo. 2018 Huang, Ren, Bao, Guo, Xiang, Jing, Shi, Zhang, Li, Tian, Kang and Guo

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Ulinastatin Inhibits Osteoclastogenesis and Suppresses Ovariectomy-Induced Bone Loss by Downregulating uPAR by Huang, J., Ren, R., Bao, Y., Guo, J., Xiang, W., Jing, X., et al. (2018). Front. Pharmacol. 9:1016. doi: 10.3389/fphar.2018.01016 ulinastatin uPAR osteoclast MAPKs NF-kB RANKL osteoporosis

In the original article, there was a mistake in Figure 1 as published. The images used for the group of OVX+U were from a different study. The corrected Figure 1 appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way.

Ulinastatin inhibits bone loss induced by OVX. (A) μ-CT images of the trabecular bone of distal femoral metaphysis from the SHAM, OVX, and OVX + ulinastatin groups. (B) The trabecular structural parameters of the distal femur: trabecular bone volume/tissue volume (BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th), and trabecular separation (Tb.Sp). Data are presented as means ± SD. n = 10 and *P < 0.05.

The original article has been updated.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.